International Journal of Hematology

, Volume 97, Issue 6, pp 743–748

Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma

Authors

    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Shuji Ozaki
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
    • Department of HematologyTokushima Prefectural Central Hospital
  • Asuka Oda
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Shiro Fujii
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Shingen Nakamura
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Hirokazu Miki
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
    • Division of Transfusion MedicineTokushima University Hospital
  • Kumiko Kagawa
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Kyoko Takeuchi
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Toshio Matsumoto
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
  • Masahiro Abe
    • Department of Medicine and Bioregulatory Sciences, Graduate School of Medical SciencesUniversity of Tokushima
Rapid Communication

DOI: 10.1007/s12185-013-1321-0

Cite this article as:
Harada, T., Ozaki, S., Oda, A. et al. Int J Hematol (2013) 97: 743. doi:10.1007/s12185-013-1321-0

Abstract

Transient inflammatory reactions have been reported in a subpopulation of patients with multiple myeloma (MM) during lenalidomide (Len) plus dexamethasone (DEX) therapy. Here, we examined serum levels of Th1 (IL-2 and IFN-γ) and Th2 cytokines (IL-6 and TNF-α) in nine refractory or relapsed MM patients treated with Len plus low-dose DEX. Six patients showed elevation of C-reactive protein (CRP) after the initiation of therapy. In these patients, IFN-γ and IL-6 were also elevated in two and three patients, respectively. The remaining three patients showed no appreciable changes in CRP or these cytokines. Furthermore, Len enhanced the production of both Th1 and Th2 cytokines in normal peripheral blood mononuclear cells and in patient bone marrow mononuclear cells containing primary myeloma cells and lymphocytes. These results suggest that the modulation of the Th1 and Th2 cytokine production by Len may contribute to transient inflammatory reaction in MM patients.

Keywords

Multiple myelomaLenalidomideInflammatory reaction

Supplementary material

12185_2013_1321_MOESM1_ESM.jpg (79 kb)

Supplementary Figure 1. Cytokine production by intracellular flow cytometric assay. RPMI 8226 and normal PBMCs in the co-culture setting (A) or patient BMMCs (B) were stimulated by Len for 48 h. Then, intracellular cytokine production was determined by flow cytometry. Representative data are shown from three independent experiments. (JPG 78.6 kb)

Copyright information

© The Japanese Society of Hematology 2013